Related Experiment Videos
Randomized multi center study comparing nephrotoxicity of ceftazidime versus the combination of piperacillin and
A W Mondorf1, C Bonsiepe, W Mondorf
1Zentrum der Inneren Medizin der Universitatskliniken Frankfurt, FRG.
Advances in Experimental Medicine and Biology
|January 1, 1989
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy.
Haemophilia : the official journal of the World Federation of Hemophilia·2013
Haemoassist--a hand-held electronic patient diary for haemophilia home care.
Haemophilia : the official journal of the World Federation of Hemophilia·2009
Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay.
Haemophilia : the official journal of the World Federation of Hemophilia·2001
The natural history of the immune response to exogenous factor VIII in severe haemophilia A.
Haemophilia : the official journal of the World Federation of Hemophilia·1999
[Thrombosis of the inferior vena cava in Behçet disease].
Wiener klinische Wochenschrift·1997
Protein-Centric Biochemistry Laboratory Experiments from Protein Quantification to Proteomics.
Advances in experimental medicine and biology·2026
Recent Applications of Mass Spectrometry at Clarkson University: An Update.
Advances in experimental medicine and biology·2026
Bottlenecks in Proteomics: An Addendum.
Advances in experimental medicine and biology·2026
Detection of Biomedically Relevant Stilbenes from Wines by Mass Spectrometry: An Update.
Advances in experimental medicine and biology·2026
Application of Ion Mobility Mass Spectrometry in Lipidomics.
Advances in experimental medicine and biology·2026
Glycomics Meets Oncology: The Role of Mass Spectrometry in Cancer Research.
Advances in experimental medicine and biology·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026